Goldman Sachs Upgrades Rocket Pharmaceuticals Following $150M Credit Facility

Key Facts

1Goldman Sachs upgraded Rocket Pharmaceuticals (RCKT) from Sell to Neutral.

2The company secured a $150 million credit facility from Hercules Capital to fund its Phase 2 Danon disease trial.

3Early Phase 2 safety data for RP-A501 showed no serious complications in the first three patients treated.

Goldman Sachs upgraded Rocket Pharmaceuticals (RCKT) from Sell to Neutral, according to Financial Modeling Prep. The upgrade follows the company's announcement that it secured a $150 million credit facility from Hercules Capital to fund its Phase 2 Danon disease trials and broader cardiovascular pipeline.

Preliminary safety data for the RP-A501 trial, reported by Business Wire, showed no serious complications in the first three patients treated under a modified protocol. RCKT closed at $2.54 on October 7, 2026, while Goldman Sachs (GS) closed at $887.21 and Hercules Capital (HTGC) closed at $16.36 on the same date.